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Abstract
Background:  To determine whether acute (single dose) and/or chronic (14-days)
supplementation of CoQ10 will improve anaerobic and/or aerobic exercise performance by
increasing plasma and muscle CoQ10 concentrations within trained and untrained individuals.
Methods: Twenty-two aerobically trained and nineteen untrained male and female subjects (26.1
± 7.6 yrs, 172 ± 8.7 cm, 73.5 ± 17 kg, and 21.2 ± 7.0%) were randomized to ingest in a double-blind
manner either 100 mg of a dextrose placebo (CON) or a fast-melt CoQ10 supplement (CoQ10)
twice a day for 14-days. On the first day of supplementation, subjects donated fasting blood samples
and a muscle biopsy. Subjects were then given 200 mg of the placebo or the CoQ10 supplement.
Sixty minutes following supplement ingestion, subjects completed an isokinetic knee extension
endurance test, a 30-second wingate anaerobic capacity test, and a maximal cardiopulmonary
graded exercise test interspersed with 30-minutes of recovery. Additional blood samples were
taken immediately following each exercise test and a second muscle biopsy sample was taken
following the final exercise test. Subjects consumed twice daily (morning and night), 100 mg of
either supplement for a period of 14-days, and then returned to the lab to complete the same
battery of tests. Data was analyzed using repeated measures ANOVA with an alpha of 0.05.
Results:  Plasma CoQ10 levels were significantly increased following 2 weeks of CoQ10
supplementation (p < 0.001); while a trend for higher muscle CoQ10 levels was observed after
acute CoQ10 ingestion (p = 0.098). A trend for lower serum superoxide dismutase (SOD) was
observed following acute supplementation with CoQ10 (p = 0.06), whereas serum
malondialdehyde (MDA) tended to be significantly higher (p < 0.05). Following acute ingestion of
CoQ10, plasma CoQ10 levels were significantly correlated to muscle CoQ10 levels; maximal
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oxygen consumption; and treadmill time to exhaustion. A trend for increased time to exhaustion
was observed following 2 weeks of CoQ10 supplementation (p = 0.06).
Conclusion:  Acute supplementation with CoQ10 resulted in higher muscle CoQ10
concentration, lower serum SOD oxidative stress, and higher MDA levels during and following
exercise. Chronic CoQ10 supplementation increased plasma CoQ10 concentrations and tended
to increase time to exhaustion. Results indicate that acute and chronic supplementation of CoQ10
may affect acute and/or chronic responses to various types of exercise.
Background
In recent years, Coenzyme Q10 (CoQ10) has gained con-
siderable attention as a dietary supplement capable of
influencing cellular bioenergetics and counteracting some
of the damage caused by free radicals [1-4]. CoQ10 is a
vitamin like, fat-soluble substance existing in all cells [5].
It is intimately involved in several important roles in the
body including the transferring of electrons within the
mitochondrial oxidative respiratory chain and hence, ATP
production; acting as an essential antioxidant and sup-
porting the regeneration of other antioxidants; influenc-
ing the stability, fluidity and permeability of membranes;
and, stimulating cell growth and inhibiting cell death [5-
7].
In clinical populations, CoQ10 has been used as a supple-
mentary treatment for chronic diseases such as Chronic
Heart Failure (CHF), muscular dystrophies, Parkinson's
disease, cancer, and diabetes [8,9]. In CHF patients, a dis-
ease characterized by lower than normal CoQ10 levels,
CoQ10 supplementation has shown to improve stroke
volume, ejection fraction and exercise capacity in several
double-blind, placebo-controlled studies [4]. In athletes,
CoQ10 deficiency may also be experienced as metabolic
stress and free radical formation is elevated during times
of intense training [7,10,11]. Thus, given our current
understanding into the functions of CoQ10 within the
body, it has been hypothesized that dietary supplementa-
tion with CoQ10 may not only be beneficial to clinical
patients, but also healthy active individuals who may
potentially experience CoQ10 deficiency [3].
While this theory is plausible, results of studies that have
evaluated the potential ergogenic value of CoQ10 in ath-
letes have reported mixed results [4]. For example, several
studies have found that CoQ10 supplementation (60–
100 mg/day for 4–8 weeks) improves aerobic power,
anaerobic threshold, exercise performance, and/or recov-
ery after exercise in trained athletes and untrained individ-
uals [12-14]. Conversely, other studies using similar
dosages (60–150 mg/day for 3–8 weeks) have found no
ergogenic benefit on maximal or submaximal exercise
capacity in untrained and trained individuals [15-19].
One possible explanation for these inconsistent findings
is that the absorption of CoQ10 into the mitochondrial
membrane or non-deficit tissues is rather inefficient. In
this regard, CoQ10 is a relatively large, hydrophobic mol-
ecule [20]. Therefore, absorption of CoQ10 into tissues is
often slow and limited. Formulations that could maxi-
mize CoQ10 absorption would not only improve its
uptake into the plasma, but potentially improve its
absorption into the skeletal muscle. Recently, the bioa-
vailability and absorptive properties of several CoQ10
preparations were examined (i.e., fast-melt tablet, effer-
vescent tablet, soft gelatin liquid capsule, and a hard shell
powdered capsule) [21]. Results indicated that the fast-
melt tablet and effervescent formulation provided a more
rapid delivery of CoQ10 to the blood, while exhibiting
similar pharmacokinetic properties compared with the
soft gel and hard capsule forms of CoQ10 [21]. These
findings suggest that provision of CoQ10 in a fast-melt or
effervescent form may facilitate CoQ10 delivery and
uptake to the muscle. Theoretically, this may enhance bio-
availability of CoQ10 and promote a greater metabolic
and/or ergogenic impact. However, the effects of acute
and chronic ingestion of a fast-melt form of CoQ10 on
muscle CoQ10 concentrations and exercise performance
is unknown. Therefore, the purpose of this study was to
determine whether acute (single-dose) and chronic (14-
days) supplementation with a fast-melt form of CoQ10
will affect muscle CoQ10 concentrations, improve anaer-
obic and aerobic performance, and/or affect markers of
oxidative stress in trained and untrained individuals.
Methods
Subjects
Twenty-two aerobically trained and nineteen untrained
male and female subjects (26.1 ± 7.6 yrs, 172 ± 8.7 cm,
73.5 ± 17 kg, and 21.2 ± 7.0%) participated in this study.
Aerobically trained individuals had been training a mini-
mum of two years for an average of 8 ± 2 hours/week, 9 ±
3 workouts/week, and averaged 68 ± 36 kilometers/week
of aerobic exercise (i.e., running, cycling and/or swim-
ming). Untrained individuals did not participate in any
regular form of aerobic exercise for at least the past year.
All subjects signed informed consent documents and the
study was approved by the Baylor University InstitutionalJournal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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Review Board prior to any data collection. Subjects were
not allowed to participate in this study if they reported
any of the following: 1) current or past history of anabolic
steroid use; 2) any metabolic disorders or taking any thy-
roid, hyperlipidmeic, hypoglycemic, anti-hypertensive, or
androgenic medications; 3) ingested any ergogenic levels
of creatine, HMB, thermogenics, ribose, pro-hormones
(i.e., DHEA, androstendione, etc.) or other purported ana-
bolic or ergogenic nutritional supplements within 2
months prior to beginning the study and to not take any
additional nutritional supplement or contraindicated pre-
scription medication during the protocol.
Experimental design
Figure 1 shows the experimental design used in this study.
The study was conducted in a randomized, double-
blinded, and placebo-controlled manner. All subjects eli-
gible to participate in the study completed a familiariza-
tion session where they were provided information (both
verbal and written) regarding the study design, testing and
supplementation protocols. Informed consent, medical
documents and training history questionnaires were also
completed at this time. Subjects were then required to per-
form an isokinetic leg extension test and 30-second anaer-
obic Wingate test to become familiar with the protocol
and equipment. The procedures for all exercise tests are
described in detail below. Following the practice trials,
subjects were scheduled to return 48 hours later for base-
line testing. Subjects were asked to not change their die-
tary habits in any way throughout the study. This was
monitored by having each subject document dietary
intake for 4 days (3 weekdays and 1 weekend day) before
each testing session. In addition, each subject was
instructed to fast for 12 hours and not to perform any
physical activity for the 48 hours preceding each testing
session.
At baseline testing (T1), subjects reported to the lab in the
morning to complete questionnaires regarding health sta-
tus. Subjects then performed three exercise tests in the fol-
lowing order: 1.) isokinetic knee extension muscle
endurance test; 2.) 30-second Wingate anaerobic capacity
test; and, 3.) a maximal cardiopulmonary graded exercise
test. Thirty minute rest periods were allocated between
each exercise test. Following baseline measurements, sub-
jects were matched based on age and aerobic capacity and
randomly separated into two groups: 1.) a dextrose pla-
cebo group; or 2.) a fast-melt CoQ10 group [Fast-Melt
Coenzyme Q10, Pharma Base, S.A. (Switzerland)]. Sub-
jects were instructed to return to the lab in 48 hours for
testing and ingestion of the first supplement.
On returning to the lab (Day 0, T2), subjects completed
the questionnaires. Prior to ingestion of the first supple-
ment dose, body mass, total body water, and body com-
position measurements were obtained. Subjects then
donated approximately 20 ml of fasting blood and
approximately 15–30 mg of muscle using standard proce-
dures described below. Subjects consumed either the pla-
cebo or CoQ10 supplement. At 60 minutes following
ingestion of the supplement, subjects performed the three
exercise tests as mentioned above with 30 minutes of
recovery between each exercise test. Additional blood
samples were taken immediately following each exercise
test. Subjects returned to the lab following 2 weeks of sup-
plementation to complete the same battery of assess-
ments. No supplement was ingested on day 14 (T3) prior
to performing the exercise tests.
Exercise protocol
Muscle endurance assessment
At baseline, day 0 and 14, subjects performed a 50-repeti-
tion Isokinetic leg extension test. Prior to testing, subjects
warmed up on a stationary bicycle for 2–3 min at a 50–60
rpm. Subjects then performed five warm-up repetitions
Schematic diagram of research design Figure 1
Schematic diagram of research design.Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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on the Biodex (Biodex Medical Systems, Shirley, NY, USA)
isokinetic leg extension machine. After these warm-up
repetitions, subjects performed unilateral leg extensions
(right leg) for one set of 50 repetitions [22] at 180 degrees/
s. Test-test reliability of this test has been shown to be 0.78
to 0.82 [23].
Anaerobic capacity assessment
At baseline, day 0, and day 14, subjects performed a 30-
second Wingate anaerobic capacity test 30 minutes fol-
lowing completion of the muscle endurance test. Subjects
warmed up for 2 min at 50–60 rpm on a stationary bicycle
ergometer before performing the Wingate test. This warm-
up was continued into the start of the sprinting portion of
the Wingate test, which allows for a flying start. The Win-
gate anaerobic capacity test was performed on the LODE
cycle ergometer (Amsterdam, Netherlands) with a resist-
ance of 0.7 Nm/kg. Test-to-test variability in performing
repeated Wingate tests in our laboratory yielded correla-
tion coefficients of r = 0.98 ± 15% for mean power.
Cardiopulmonary assessment
At baseline, day 0, and 14, subjects performed a volitional
maximal cardiopulmonary exercise test according to the
Bruce protocol 30 minutes following the anaerobic capac-
ity test [24]. Participants were instructed to perform the
test for as long as possible to ensure a true maximal
attempt. Standard ACSM test termination criteria were
monitored and followed throughout each test [25]. Meta-
bolic gases were obtained with the Parvo Medics 2400
TrueMax metabolic measurement system (Sandy, UT,
USA) on a Trackmaster TMX425C treadmill (Newton, KS,
USA). The mean coefficient of variation (assessing maxi-
mum oxygen consumption) for this protocol was 6.5%
(range, 2–14%) [24]. Ventilatory threshold (VANT) was
expressed as a percentage maximal oxygen consumption
(mL·kg-1·min-1). To determine VANT, data from the
graded exercise test for minute ventilation (VE), ventila-
tion equivalent of VO2 (VE/VO2), and ventilation equiva-
lent of VCO2 (VE/VO2) were plotted against exercise time
(i.e. workload) and analyzed manually by an experienced
exercise physiologist in a blinded manner.
Supplementation protocol
Subjects were assigned in a double-blind and randomized
manner to ingest a dextrose placebo (CON, n = 20) or fast-
melt CoQ10 formulation (CoQ10, n = 21). Subjects were
matched into one of two groups according to age and aer-
obic capacity. Subjects were required to initially ingest 2
capsules (100 mg) prior to exercise performance testing
on day 0. Following testing on day 0, subjects continued
consuming 100 mg twice daily (morning and night) for
14 days. Supplements were prepared in tablet form and
packaged in generic bottles for double blind administra-
tion by Pharma Base, S.A. (Switzerland). Supplementa-
tion compliance was monitored by having the subjects
return empty bottles of the supplement at the end of 14
days of supplementation.
Procedures
Dietary inventories
Prior to each testing session, subjects were instructed to
record all food and fluid intake over a 4-day period, which
was reflective of their normal dietary intake and to include
one weekend day. Dietary inventories were then reviewed
by a registered dietician and analyzed for average energy
and macronutrient intake using the ESHA Food Processor
(Version 8.6) Nutritional Analysis software (Salem, OR,
USA).
Anthropometrics
At the beginning of every testing session, subjects had
their height and body mass measured according to stand-
ard procedures using a Healthometer (Bridgeview, IL,
USA) self-calibrating digital scale with an accuracy of ±
0.02 kg.
Body composition
Total body water was estimated using a Xitron 4200 Bioe-
lectrical Impedance Analyzer (San Diego, CA). Whole-
body composition measurements (excluding cranium)
were determined with a Hologic Discovery W Dual-
Energy X-ray Absorptiometer (DEXA; Hologic, Bedford,
MA, USA) by using procedures previously described
[26,27]. Test-retest reliability studies performed on male
athletes with this DEXA machine revealed mean deviation
for total bone mineral content and total fat free/soft tissue
mass of 0.31% with a mean intraclass correlation of
0.985.
Blood collection
Subjects were required to fast for 12 hrs prior to donating
approximately four teaspoons (20 milliliters) of venous
blood from an antecubital vein using standard phlebot-
omy procedures. Blood analyzed for CoQ10 was placed in
a test tube containing heparin as the anticoagulant and
immediately centrifuged at 3000 g using a standard bench
top centrifuge (Cole Palmer, Vernon Hills, IL, Model #
17250-10) for 15 minutes at room temperature. Plasma
was separated and stored at -80°C in polypropylene tubes
for later analysis. Blood analyzed for makers of oxidative
stress and clinical chemistry panels were placed into two
serum separation tubes and immediately centrifuged at
1100 g for 15 min. Serum was separated and stored at -
80°C in polypropylene tubes for later analysis. Finally,
blood was collected in a single lavender top tube contain-
ing K2 EDTA and refrigerated for approx 4–6 h for subse-
quent complete blood count with platelet differentials
analysis (hemoglobin, hematocrit, red blood cell counts,
MCV, MCH, MCHC, RDW, white blood cell counts, neu-Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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trophils, lymphocytes, monocytes, eosinophils,
baosphils) using an Abbott Cell Dyn 3500 (Abbott Labo-
ratories, Abbott Park, IL) automated hematology ana-
lyzer. Whole blood was only analyzed pre- and post-
exercise.
Clinical chemistry analysis
Serum samples were analyzed using a Dade Behring
Dimension RXL (Deerfield, IL, USA) automated clinical
chemistry analyzer that was calibrated and optimized
according to manufacturer guidelines. This analyzer has
been known to be highly valid and reliable in previously
published reports [28]. Each serum sample was assayed
for a standard complete metabolic panel [(glucose, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), albumin, globulin,
sodium, chloride, calcium, carbon dioxide, total
bilirubin)], lipid panel [(triglycerides, total cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), total cholesterol:HDL)] and clinical markers of
protein and fatty acid metabolism [(uric acid, creatinine,
blood urea nitrogen (BUN), BUN:creatinine ratio, total
protein, creatine kinase (CK), ketones (betahydroxybu-
tyrate), and lactate dehydrogenase (LDH)]. Test to test
reliability (within and between) of performing these
assays ranged from 2 to 6% for individual assays with an
average CV of ± 3%. Samples were run in duplicate to ver-
ify results if the observed values were outside control val-
ues and/or clinical norms according to standard
procedures.
Markers of oxidative stress
Serum samples were assayed using standard commercially
available spectrophotometric assay kits (Caymen Chemi-
cal Company, Michigan, USA) for Thiobarbituric Acid
Reactive Substance (TBARS, Malondialdehyde-MDA) and
Superoxide Dismutase (SOD). Enzyme immunoassay
(EIA) was used to measure serum 8-Isoprostane. Serum
concentrations were determined using a Wallac-Victor IV
(Perkin-Elmer Life Sciences, Boston, MA) micro plate
reader at an optical density of 450 nm against a known
standard curve using standard procedures. Test to test reli-
ability (within and between) of performing these assays
ranged from 3 to 6% for individual assays with an average
CV of ± 4%.
Muscle sample collection
Fine Needle Aspiration (FNA) muscle biopsies were taken
on days 0 and 14 prior to, and following performance
tests in order to examine total CoQ10 content in the mus-
cle according to standard procedures [29]. Participants
were instructed to refrain from exercise 48 h prior to each
muscle biopsy. Muscle was extracted from the lateral por-
tion of the vastus lateralis midway between the patella and
iliac crest of the dominant leg using a TRU-CORE® 1 Auto-
matic Reusable Biopsy Instrument (Angiotech, Medical
Device Technologies, INC., Gainsville, Florida, USA).
Briefly, 0.5 ml of 1.0% Lidocaine HCl was injected subcu-
taneously prior to making a small pilot hole with a 23
gauge sterile needle. The biopsy needle was placed into
the biopsy device and the inserted into the previously
made pilot hole (a depth of about 5–10 mm). A muscle
sample was obtained by the activation of a trigger button,
which unloaded the spring and activated the needle to
collect a muscle piece. The biopsy needle was removed
from the pilot hole and the muscle specimen was
removed from the biopsy needle using a sterile scalpel and
immediately frozen in liquid nitrogen and stored at -80°C
for further analyses. This whole biopsy procedure was
repeated two to three times in order to obtain sufficient
muscle tissue (15–30 mg).
CoQ10 determination
Frozen plasma and muscle samples were sent to Craft
Technologies (Wilson, NC, USA) for assay of plasma and
muscle CoQ10 concentrations using methods described
by Tang et al., [29] and Rousseau and Varin [30]. Total
CoQ10 was determined by summing the oxidized and
reduced forms.
Statistical analysis
Data are presented in all tables and throughout the text as
mean (± SD). Plasma and muscle CoQ10 levels and mark-
ers of oxidative stress were analyzed using 2 × 2 × 2 × 4
(group × training status × gender × exercise [Baseline, Iso-
kinetic, Wingate, Cardiopulmonary]) repeated measures
ANOVA to assess the changes in plasma and muscle
CoQ10 levels and markers of oxidative stress following
acute (T2) and chronic (T3) supplementation. Delta
scores (post minus pre values) were calculated for each
exercise test (Isokinetic, Wingate, Cardiopulmonary) and
analyzed using repeated measures ANOVA. All remaining
data were analyzed using 2 × 2 × 2 × 3 (group × training
status × gender × day [baseline, day 0 and 14]) repeated
measures ANOVA. LSD pairwise comparisons were used
to analyze any significant group × time interaction effects.
Pearson product correlations were used to determine any
relationship between criterion variables and an alpha
level of 0.05 was adopted throughout to prevent any Type
I statistical errors.
Results
Subject characteristics
There were no baseline differences in the age, body weight
or height between the two groups (see Table 1).
Side effects
No adverse events were reported concerning the supple-
mentation or study protocol. No reports of medical prob-Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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lems or side effects were indicated in post-study
questionnaires administered in a blinded manner.
Clinical safety markers
Complete blood counts with platelet differentials were
run on all whole blood samples and a standard clinical
safety panels was completed on all serum samples at base-
line, day 0 and day 14. While some hematological varia-
bles did report main effects over time, no significant
group × time interaction effects were observed and none
of these changes occurred outside of the clinically
accepted normative values for these variables [31]. There-
fore, these data are not reported. No significant main or
group × time interaction effects (p < 0.05) were found for
kidney/liver enzymes [e.g., GGT (p = 0.51), AST (p =
0.14), ALT (p = 0.43), ALP (p = 0.27)] or markers of pro-
tein breakdown [e.g., uric acid (p = 0.38), billirubin (p =
0.82), creatinine (p = 0.73), BUN:creatinine ratio (p =
0.80), total protein (p = 0.30), CK (p = 0.87)].
Lipid panels
Table 2 presents fasting lipid profile data observed
throughout the study. No significant differences were
reported for total (HDL and LDL) cholesterol and choles-
terol:HDL ratio when all groups were included in the
analysis (see Table 2). However, a significant group × time
interaction was found for triglyceride levels (p < 0.05),
with subsequent post-hoc analysis revealing a significant
decrease in serum triglyceride levels in the CoQ10 com-
pared to CON over the 2 week supplementation period (p
< 0.05). It should be noted that triglyceride levels were
below the normal range in both groups and such a
decrease observed in the supplement group could prima-
rily be due to normal physiological variation.
Nutritional intake and compliance
Nutritional intake was monitored over a 4-day period
prior to each testing session and analyzed for energy
intake, total carbohydrates, total protein and total fat (see
Table 3). A significant group × time interaction was
observed for total calories and protein (p < 0.05). No
other statistically significant interactions were observed
across groups.
Body composition
Body composition was assessed at baseline, day 0 and 14
to determine changes in bone, fat and lean changes over
the course of the investigation (see Table 4). No signifi-
cant differences were observed between groups in changes
in total body water, bone mass, lean body mass, or body
fat percentage over the course of the investigation.
Muscle endurance assessment
A 50 repetition isokinetic leg extension test was performed
at baseline, day 0, and day 14 to assess indices of muscle
Table 1: Subject Baseline Characteristics
Variable CoQ10 Placebo
Age (yr) 25.76 ± 7.67 25.61 ± 8.07
Body Weight (kg) 76.02 ± 18.71 71.94 ± 18.12
Height (cm) 173.48 ± 7.42 168.18 ± 26.48
Data are means and ± standard deviations of mean
Table 2: Lipid Panels for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
Total Cholesterol (mg·dl-1) Day 0 165 ± 32 172 ± 31 Group 0.126
Day 14 167 ± 25 182 ± 30 Time 0.151
G × T 0.621
Triglycerides (mg·dl-1) Day 0 95 ± 42 78 ± 26 Group 0.552
Day 14 85 ± 43† 91 ± 36† Time 0.985
G × T 0.019
HDL Cholesterol (mg·dl-1) Day 0 53 ± 12 58 ± 15 Group 0.443
Day 14 54 ± 10 59 ± 15 Time 0.112
G × T 0.296
LDL Cholesterol (mg·dl-1) Day 0 97 ± 28 99 ± 22 Group 0.827
Day 14 97 ± 24 104 ± 24 Time 0.004
G × T 0.121
Chol:HDL Day 0 3.19 ± 0.81 3.07 ± 0.60 Group 0.431
Day 14 3.17 ± 0.74 3.19 ± 0.64 Time 0.183
G × T 0.201
Data are means and ± standard deviations of mean.
† represents p < 0.05 difference between groupsJournal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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endurance performance (see Table 5). No statistically sig-
nificant interactions were observed among groups in indi-
ces of muscle endurance (peak torque extension [EXT],
peak torque flexion [FLX], total work EXT, total work FLX,
work fatigue EXT, work fatigue FLX, average [AVG] power
EXT, AVG power FLX).
Anaerobic capacity assessment
A 30 second Wingate anaerobic capacity test was per-
formed at baseline, day 0, and day 14 to assess indices of
anaerobic performance (see Table 6). No statistically sig-
nificant interactions were observed among groups in
anaerobic capacity indices (peak power, mean power, rate
to fatigue, or total work). A trend towards a significant
main effect for time was observed in rate to fatigue per-
formance (p = 0.06), indicating an increase in rate to
fatigue from baseline (T1) to day 14 (T3).
Aerobic capacity assessment
A maximal graded exercise test was performed at baseline,
day 0, and day 14 to assess aerobic capacity and perform-
ance (see Table 7). A trend towards a significant group ×
time interaction was observed in time to exhaustion (p =
0.06), indicating the CoQ10 group exercised longer com-
pared to the CON group following 2 weeks of supplemen-
tation. No statistically significant interactions were
observed across groups in other indices of aerobic capacity
(i.e., oxygen consumption, RER, or ventilatory anaerobic
threshold).
Table 3: Nutritional Intake Analyses for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
Energy Intake (kcal·kg·d-1) Baseline 2591 ± 613 2103 ± 598† Group 0.210
Day 0 2668 ± 849 1979 ± 677† Time 0.461
Day 14 2514 ± 474 2227 ± 608 G × T 0.023
Carbohydrate Intake (g·kg·-1·d-1) Baseline 315 ± 85 267 ± 82 Group 0.420
Day 0 319 ± 116 247 ± 109 Time 0.410
Day 14 318 ± 66 287 ± 72 G × T 0.132
Protein Intake (g·kg·-1·d-1) Baseline 114 ± 44 99 ± 32 Group 0.112
Day 0 124 ± 58 94 ± 34† Time 0.243
Day 14 104 ± 35 102 ± 12 G × T 0.012
Fat Intake (g·kg·-1d·-1) Baseline 97 ± 40 70 ± 23 Group 0.120
Day 0 104 ± 47 71 ± 28 Time 0.071
Day 14 90 ± 36 69 ± 23 G × T 0.081
Data are means and ± standard deviations of mean.
† represents p < 0.05 difference between groups
Table 4: Body Composition Measurements for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
BMC Day 0 2805 ± 694 2584 ± 487 Group 0.352
(g) Day 14 2788 ± 706 2596 ± 452 Time 0.485
G × T 0.219
Fat Mass (kg) Day 0 15385 ± 7686 15128 ± 6307 Group 0.443
Day 14 15252 ± 7740 15284 ± 6342 Time 0.312
G × T 0.196
Lean Mass (kg) Day 0 55274 ± 13638 51221 ± 11336 Group 0.627
Day 14 55260 ± 13794 51311 ± 11372 Time 0.214
G × T 0.121
Body Fat (%) Day 0 21 ± 7.2 22 ± 7.0 Group 0.731
Day 14 21 ± 7.0 22 ± 6.9 Time 0.183
G × T 0.201
Data are means and ± standard deviations of meanJournal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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Markers of oxidative stress
Table 8 presents markers of oxidative stressed evaluated in
this study. A significant main effect for time was observed
in serum SOD levels, indicating an increase following all
exercise performance measurements on day 0 (T2) and
day 14 (T3). However, a trend towards a significant group
× time interaction (p = 0.06) was revealed with subse-
quent post-hoc analysis indicating that although SOD lev-
els increased over time. SOD levels after the isokinetic
muscle endurance test were significantly lower in the
CoQ10 compared to CON group (p < 0.05). A significant
main effect for time was also observed in serum 8-ISO and
Table 5: Isokinetic Muscle Endurance Indices for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
Peak Torque EXT (N/m) Baseline 132 ± 42 110 ± 38 Group 0.181
Day 0 127 ± 37 110 ± 34 Time 0.265
Day 14 132 ± 34 107 ± 35 G × T 0.495
Peak Torque FLX (N/m) Baseline 72 ± 28 65 ± 26 Group 0.218
Day 0 75 ± 28 66 ± 28 Time 0.534
Day 14 73 ± 24 65 ± 28 G × T 0.488
Total Work EXT (N/m) Baseline 4047 ± 1218 3391 ± 992 Group 0.826
Day 0 3955 ± 1114 3352 ± 936 Time 0.308
Day 14 4073 ± 1116 3242 ± 921 G × T 0.442
Total Work FLX (N/m) Baseline 2213 ± 847 1962 ± 891 Group 0.127
Day 0 2203 ± 877 1996 ± 963 Time 0.493
Day 14 2230 ± 822 1866 ± 839 G × T 0.591
Work Fatigue EXT (%) Baseline 48 ± 15 41 ± 17 Group 0.112
Day 0 46 ± 14 37 ± 19 Time 0.160
Day 14 48 ± 11 36 ± 20 G × T 0.309
Work Fatigue FLX (%) Baseline 46 ± 20 43 ± 29 Group 0.132
Day 0 51 ± 14 35 ± 30 Time 0.534
Day 14 51 ± 16 44 ± 14 G × T 0.192
AVG Power EXT (Watts) Baseline 117 ± 36 95 ± 30 Group 0.476
Day 0 115 ± 34 95 ± 27 Time 0.315
Day 14 117 ± 33 95 ± 30 G × T 0.351
AVG Power FLX (Watts) Baseline 61 ± 25 52 ± 25 Group 0.106
Day 0 62 ± 26 54 ± 27 Time 0.334
Day 14 62 ± 24 52 ± 26 G × T 0.402
Data are means and ± standard deviations of mean
Table 6: Wingate Anaerobic Power Indices for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
Peak Power (Watts) Baseline 1162 ± 436 1013 ± 417 Group 0.359
Day 0 1169 ± 421 1079 ± 416 Time 0.138
Day 14 1209 ± 420 1069 ± 400 G × T 0.587
Mean Power (Watts) Baseline 592 ± 210 535 ± 181 Group 0.427
Day 0 594 ± 209 545 ± 180 Time 0.137
Day 14 603 ± 211 548 ± 181 G × T 0.883
Rate to Fatigue (Watts) Baseline 33 ± 14 27 ± 15 Group 0.239
Day 0 34 ± 15 30 ± 15 Time 0.060
Day 14 35 ± 15 29 ± 14 G × T 0.623
Data are means and ± standard deviations of meanJournal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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MDA levels (p < 0.05 and p < 0.001, respectively) indicat-
ing an increase over time following all exercise perform-
ance measurements on day 0 (T2) and day 14 (T3).
Similar to SOD levels, a significant group × time interac-
tion (p < 0.05) was also revealed on day 0. However, post-
hoc analysis indicated significantly lower MDA levels in
Table 7: Aerobic Power Indices for the CoQ10 and Placebo (CON) groups.
Variable Time CoQ10 Placebo Significance
Oxygen Consumption (mL·kg-1·min-1) Baseline 42.3 ± 9.1 43.9 ± 9.0 Group 0.358
Day 0 42.9 ± 8.5 45.5 ± 7.9 Time 0.815
Day 14 42.1 ± 8.5 43.4 ± 9.6 G × T 0.293
Maximal Respiratory Exchange Ratio Baseline 1.16 ± 0.09 1.17 ± 0.08 Group 0.564
Day 0 1.18 ± 0.09 1.19 ± 0.04 Time 0.134
Day 14 1.16 ± 0.09 1.16 ± 0.11 G × T 0.546
Time to exhaustion (Min) Baseline 12.9 ± 2.4 13.6 ± 2.3 Group 0.332
Day 0 13.1 ± 2.8 13.8 ± 2.1 Time 0.110
Day 14 13.3 ± 2.3 13.7 ± 2.4 G × T 0.060
Ventilatory Threshold (% VO2max) Baseline 70.4 ± 12.9 71.35 ± 11.6 Group 0.210
Day 0 70.7 ± 11.4 72.30 ± 11.4 Time 0.951
Day 14 72.1 ± 12.0 70.00 ± 11.9 G × T 0.536
Data are means and ± standard deviations of mean
Table 8: Time Course of Markers of Oxidative Stress for the CoQ10 and Placebo (CON) subjects taken immediately after each 
performance test.
Variable Time CoQ10 Placebo Significance
Superoxide Dismutase (SOD) (U/ml) Baseline T2 1.52 ± 0.31 1.59 ± 0.27 Group 0.103
Isokinetic T2 1.56 ± 0.24 1.80 ± 0.39 Time 0.001
Wingate T2 1.75 ± 0.23 1.70 ± 0.22 G × T 0.060
GXT T2 1.68 ± 0.17 1.70 ± 0.26
Baseline T3 1.61 ± 0.40 1.77 ± 0.52 Group 0.296
Isokinetic T3 1.74 ± 0.37 1.90 ± 0.54 Time 0.001†
Wingate T3 1.91 ± 0.39 2.06 ± 0.51 G × T 0.966
GXT T3 1.81 ± 0.42 1.98 ± 0.50
Thiobarbituric Acid Reactive Substance (TBARS) (µM) Baseline T2 2.79 ± 1.02 2.50 ± 1.34 Group 0.042
Isokinetic T2 4.11 ± 1.71 3.24 ± 1.69 Time 0.001
Wingate T2 4.72 ± 2.14 3.35 ± 1.57† G × T 0.018†
GXT T2 5.09 ± 2.23 3.62 ± 1.90†
Baseline T3 3.03 ± 1.03 3.12 ± 1.26 Group 0.540
Isokinetic T3 4.28 ± 1.72 4.23 ± 1.47 Time 0.001
Wingate T3 4.25 ± 1.17 4.85 ± 2.11 G × T 0.534
GXT T3 5.32 ± 2.09 5.52 ± 1.89
8-Isoprostane (pg/ml) Baseline T2 76 ± 28 78 ± 33 Group 0.616
Isokinetic T2 86 ± 63 88 ± 61 Time 0.050
Wingate T2 105 ± 72 99 ± 63 G × T 0.431
GXT T2 108 ± 67 110 ± 62
Baseline T3 84 ± 46 79 ± 35 Group 0.334
Isokinetic T3 101 ± 37 124 ± 75 Time 0.001
Wingate T3 114 ± 53 122 ± 69 G × T 0.553
GXT T3 99 ± 49 111 ± 87
Data are means and ± standard deviations of mean.
† represents p < 0.05 difference between groupsJournal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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the CON group compared to CoQ10 group following the
anaerobic Wingate test and aerobic capacity test (p <
0.05). No other significant interactions were observed.
Plasma and Muscle CoQ10 Concentration
Total plasma CoQ10 content data are presented in Figure
2. A significant main effect for time was observed in
plasma CoQ10 (p < 0.001). A significant group × time
interaction was also observed in plasma CoQ10 (p <
0.001) indicating a significant increase in plasma CoQ10
in the CoQ10-supplemented group compared to CON.
No other significant effects were observed.
Muscle total CoQ10 content data are presented in Figure
3. A trend towards a significant group × time interaction
(p = 0.098) was observed on day 0 (T2), indicating higher
muscle CoQ10 levels (mcg/mg) following an acute inges-
tion of CoQ10. A trend towards a significant group × gen-
der (p = 0.09) and training status × gender (p = 0.06)
interaction were observed, indicating higher levels of
CoQ10 in both trained and male subjects respectively. No
significant interactions were observed following chronic
supplementation.
Correlation analysis
Following acute ingestion of CoQ10, plasma CoQ10 was
significantly correlated to muscle CoQ10 levels; maximal
oxygen consumption; and treadmill time to exhaustion.
No other significant correlations were observed following
acute and chronic supplementation (see Table 9).
Discussion
The results from the present study demonstrate that a fast-
melt form of CoQ10 is a safe and effective supplement
that prolongs exercise performance in healthy individuals.
Further, acute CoQ10 supplementation increased total
CoQ10 concentration within the skeletal muscle and low-
ered plasma oxidative stress (SOD) during and following
exercise. Though there is evidence in the literature to sug-
gest a possible therapeutic role for CoQ10 in human dis-
eases such as CHF, the potential ergogenic value in
healthy trained and untrained individuals is less clear.
Studies that have reported improvements in aerobic
power, anaerobic threshold, and/or recovery following
CoQ10 supplementation have not generally been pub-
lished in peer-reviewed journals [4,13]. To our knowl-
edge, this is the first study to demonstrate both
improvements in exercise performance and increased
muscle CoQ10 concentration in healthy trained and
untrained humans following CoQ10 supplementation.
In the current study, both acute and chronic CoQ10 sup-
plementation had no significant effect of indices of mus-
cle endurance and anaerobic capacity as determined by an
isokinetic 50-repetition test and a 30-second Wingate
anaerobic capacity test. Similarly, no significant differ-
ences were observed among groups in maximal oxygen
uptake (VO2max) or ventilatory anaerobic threshold fol-
lowing CoQ10 supplementation. These findings are in
line with a number of previous studies [3,15,16,19] which
have also failed to demonstrate performance-enhancing
effects in trained athletes and/or untrained individuals
following CoQ10 supplementation. Recently, Zhou and
colleagues [3] investigated the effects of 4 weeks of
CoQ10 supplementation on aerobic power, ventilatory
Time course of muscle CoQ10 concentration Figure 3
Time course of muscle CoQ10 concentration. Data 
(mean ± SD) represents total muscle CoQ10 concentration 
(ug/mg muscle) for both CoQ10 and placebo control groups 
taken pre and immediately post the final performance test on 
day 0 (T2) and day 14 (T3).
Time course of plasma CoQ10 concentration Figure 2
Time course of plasma CoQ10 concentration. Data 
(mean ± SD) represents total plasma CoQ10 concentration 
(ug/ml) for both CoQ10 and placebo control groups taken 
prior to, and immediately after each performance test on day 
0 (T2) and day 14 (T3). † represents (p < 0.05) difference 
from control.Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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threshold and exercise economy of healthy males. Results
showed no significant changes in aerobic performance
(VO2max, ventilatory threshold) or exercise economy in
response to supplementation. Further, though CoQ10
concentration was elevated within the plasma, no signifi-
cant increases were observed in the muscle. Thus, the
authors concluded that the lack of ergogenic benefit was
likely due to an inability of supplementation protocol to
increase CoQ10 concentration within the muscle [3].
Similar to Zhou and coworkers [3], results from the
present study showed a significant increase in plasma
CoQ10 concentration following chronic supplementa-
tion. However, contrary to the observations of Zhou et al.,
[3], the present study showed a strong trend (p = 0.06) for
increased time to exhaustion following CoQ10 supple-
mentation. In addition, acute CoQ10 supplementation
tended to increase CoQ10 levels within the muscle, albeit
not significantly (p = 0.09). Though no significant
changes were observed following chronic supplementa-
tion, it is evident from Figure 4 that muscle CoQ10 con-
centration was generally higher after baseline in the
CoQ10-supplemented group compared to placebo group.
In fact, muscle CoQ10 levels declined in the placebo
group over the 2-week period. These findings indicate that
ingestion of a fast-melt form of CoQ10 will increase
plasma availability of CoQ10 and may also influence
muscle concentrations on an acute and/or chronic basis.
However, more research is needed before definitive con-
clusions can be drawn.
In the present study, the pre-supplementation concentra-
tion of muscle CoQ10 (14.96 ± 10.3 µg/g tissue) was
comparable to those reported by Boitier et al., [32] (19.0
± 4.8 µg/g) and Pastore et al., [33] (18.34 ± 5.5 pmol/mg
tissue). Conversely, Lamperti and colleagues [34]
observed higher CoQ10 mean values of 27.64 ± 4.4 µg/g
fresh tissue, following analysis of 121 healthy human
muscle samples. In the current study, muscle tissue was
initially frozen and then subsequently analyzed 2–3
months following the final data collection. This could
explain the lower mean values observed in the present
study compared to those reported by Lamperti et al., [34].
Approximately one half of CoQ10 in the body resides in
the inner mitochondrial membrane [10]. CoQ10 is nor-
mally localized in the central hydrophobic portion of the
membrane and thus, it has been suggested that its concen-
tration may not be able to increase freely within the mem-
brane due to physical limits and potential destabilization
of the bilayer structure [35]. A number of human studies
support this view that uptake of exogenous CoQ10 (e.g.,
120–150 mg of CoQ10 for 4–6 weeks) by tissues other
than plasma and liver is very low or absent [3,16,36].
However, recent findings in young rodents argue against
such a viewpoint, and suggest dietary supplementation
with CoQ10 can lead to elevated CoQ10 levels within the
mitochondria of the skeletal muscle [37]. One possible
factor that may limit augmentation of CoQ10 in tissues in
response to exogenous intake (oral intake) is duration.
Table 9: Correlation Data with Baseline Plasma CoQ10 levels
Variable Significance
Muscle Total CoQ10 (mcg/mg) T2 pre ¥ r value 0.423
p value 0.007
Muscle Total CoQ10 (mcg/mg) T2 post r value 0.189
p value 0.250
Muscle Total CoQ10 (mcg/mg) T3 pre r value 0.247
p value 0.125
Muscle Total CoQ10 (mcg/mg) T3 post r value 0.244
p value 0.134
Oxygen Consumption (mL·kg-1·min-1) T1 ¥ r value 0.389
p value 0.013
Oxygen Consumption (mL·kg-1·min-1) T2 ¥ r value 0.381
p value 0.017
Oxygen Consumption (mL·kg-1·min-1) T3 ¥ r value 0.429
p value 0.006
Time to exhaustion (Min) T1 ¥ r value 0.419
p value 0.007
Time to exhaustion (Min) T2 ¥ r value 0.454
p value 0.004
Time to exhaustion (Min) T3 ¥ r value 0.485
p value 0.001
¥ represents significantly correlated to baseline plasma CoQ10 levels
Delta changes from baseline for muscle CoQ10 concentra- tion Figure 4
Delta changes from baseline for muscle CoQ10 con-
centration. Data (mean ± SD) represents delta scores (post 
minus pre values) for each performance test (Isokinetic, 
Wingate, Cardiopulmonary), both CoQ10 and placebo con-
trol groups on day 0 (T2) and day 14 (T3).Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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Although the dosage in the current study was similar to
previous studies (i.e., 200 mg vs 150 mg), most studies
only examined the chronic effects of CoQ10 supplemen-
tation on intramuscular CoQ10 levels [3,16,36]. In the
current study, muscle CoQ10 concentration increased
within about 2 hours of ingestion. Muscle CoQ10 concen-
trations remained above baseline values after 2 weeks of
supplementation albeit to a much lesser degree (Figure 4).
It could be suggested that pharmacokinetics properties of
CoQ10 uptake into the muscle is similar to that of creat-
ine monohydrate. In this regard, following chronic creat-
ine supplementation, there appears to be a maximal limit
and/or down regulation of creatine transporters, eventu-
ally leading to a plateau or even a decrease in intramuscu-
lar creatine levels over time [38]. Such an effect could
explain why previous studies have failed to show any
increases in muscle CoQ10 concentration following 4–6
weeks of supplementation. However, whether a maximal
limit and/or down regulation in the transport of CoQ10
into the muscle occurs following chronic CoQ10 supple-
mentation is highly speculative and requires further inves-
tigation
It is well established that CoQ10 is synthesized de novo in
all tissues, and hence, under normal circumstances, most
tissues are not dependent on an exogenous supply of
CoQ10. However, under certain conditions such as oxida-
tive stress and aging, endogenous production may not
meet the demands for CoQ10 [39], and thus uptake may
be increased. In the current study, it is evident that intra-
muscular CoQ10 levels increased following each testing
session (T2 Pre to Post and T3 Pre to Post); while the pla-
cebo group showed an overall decrease in intramuscular
CoQ10 levels (Figure 4). This may suggest an enhanced
uptake of exogenous CoQ10 from the plasma as a conse-
quence of increased metabolism in active tissue. However,
this will require further investigation. An alternative
hypothesis is that since the new "fast-melt" CoQ10 for-
mulation has demonstrated enhanced absorption kinetics
into the blood stream compared to previous commer-
cially available formulations [21], the increased bioavail-
ability may enhance greater uptake into the muscle.
However, additional research will be needed to examine
this hypothesis as well.
Increased muscle CoQ10 concentration could explain the
increased time to exhaustion observed in the current
study. It is has been previously suggested that the CoQ10
redox shuttle is a rate limiting step in the oxidative phos-
phorylation pathway [40]. Hence, an increase in CoQ10
content within the mitochondria would potentially
enhance the oxidative phosphorylation process and sub-
sequently prolong exercise performance [3]. It is well
known that approximately 3 minutes is required for oxy-
gen consumption to reach a steady state at the beginning
of a moderate exercise at constant workload [41]. One fac-
tor that determines how quickly oxygen consumption
rises is mitochondrial density (i.e. the amount of enzymes
in oxidative phosphorylation) [42]. Zhou and colleagues
[3] demonstrated a trend for decreased oxygen deficit (an
indirect indicator of mitochondrial function) in response
to 4 weeks CoQ10 supplementation. However, due to a
small sample size and no change in muscle CoQ10 con-
centration, authors were unable to determine any signifi-
cance behind such an observation. In the current study,
although oxygen deficit was not measured, time to
exhaustion and muscle CoQ10 concentration was
increased following supplementation. The increased time
to exhaustion observed in the present study may be indi-
rect evidence of enhanced oxidative phosphorylation.
However, further research examining mitochondrial
enzymes would be needed confirm such observations.
In addition, it is speculated that increased muscle per-
formance might be due to the antioxidant effect of CoQ10
supplementation and/or its potential action on the central
nervous system [13]. In a single-blind fashion, Bonetti
and colleagues, [13] reported an increase in maximal
workload completed at exhaustion following 8 weeks of
CoQ10 supplementation [100 mg/day]. No significant
changes in VO2max and anaerobic threshold levels were
observed. The authors concluded that the increased maxi-
mum workload at exhaustion, without signs of improved
aerobic power (VO2max) and/or ventilator threshold
(similar to that observed in the current study), could be
related to the protective activity of CoQ10 on the muscu-
lar membrane (antioxidant effect) [13]. In the current
study, only serum markers of oxidative stress (i.e., SOD, 8-
Isoprostane, and MDA activity) were measured. SOD
activity is a marker of cellular antioxidant defenses and an
indirect marker of oxidative damage (i.e. an increase in
serum SOD activity indicates an increased presence of
superoxide radical in the serum, hence, increased oxida-
tive stress). 8-Isoprostane is a member of the eicosanoid
family and is produced by random oxidation of tissue
phospholipids by oxygen radicals and is therefore a direct
marker of oxidative stress. MDA is a naturally occurring
product of lipid peroxidation and similar to 8-Isopros-
tane, is a direct maker of oxidative stress.
The baseline values for each of these markers were similar
to previous studies [43,44]. As expected, all markers of
oxidative stress increased over time during each testing
session (T2 and T3). Acute and chronic CoQ10 supple-
mentation had no significant effect on 8-isoprostane lev-
els during exercise. However, significant differences were
observed in serum SOD and MDA among groups. In this
regard, serum SOD levels were significantly lower in the
CoQ10 group compared to placebo group (p < 0.05) fol-
lowing the isokinetic muscle endurance test. Additionally,Journal of the International Society of Sports Nutrition 2008, 5:8 http://www.jissn.com/content/5/1/8
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serum MDA levels were significantly higher in the CoQ10
compared to placebo group (p < 0.05) following the Win-
gate anaerobic capacity test and aerobic capacity test.
Although previous research has demonstrated decreased
oxidative stress following CoQ10 supplementation [45],
such effects have only been observed in diseased states.
Indeed, a recent study showed improved extracellular
SOD activity and endothelium-dependent vasodilation
following oral ingestion of CoQ10 (300 mg/day for 4
weeks) in patients with coronary artery disease [46].
Therefore, this is the first study to the author's knowledge,
to show a decrease in SOD activity following CoQ10 sup-
plementation in healthy individuals.
It is not apparent why serum MDA levels were signifi-
cantly higher in the CoQ10 group compared to placebo
group following the Wingate anaerobic capacity test and
aerobic capacity test. It has been suggested that although
TBARS is most widely employed assay used to determine
lipid peroxidation, that compounds other than MDA may
interfere with the specificity of this assay [47]. Therefore,
any changes in serum MDA concentration could be due to
interference from other compounds rather than lipid per-
oxidation. However, whether this explains the different
responses observed in markers of oxidative stress requires
further investigation.
In conclusion, the present study demonstrated that a fast-
melt CoQ10 formulation appears to be a safe dietary sup-
plement that tended to increase the duration of exercise to
exhaustion in healthy untrained and trained individuals.
Acute supplementation with CoQ10 resulted in higher
muscle CoQ10 concentration and lower serum SOD oxi-
dative stress during and following exercise. The observed
increase in exercise performance could be due to a combi-
nation of an enhanced oxidative phosphorylation within
the mitochondria and/or enhanced antioxidant protec-
tion. However, further research is clearly needed to eluci-
date such mechanisms.
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